Prof. Wischik, Chairman of TauRx Therapeutics, will present a scientific update at the 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy on the company’s global Phase 3 clinical trials; its tau aggregation inhibitor, LMTX™, is aimed at halting the progression of Alzheimer’s
ABERDEEN, Scotland, 27 March 2014 – TauRx Therapeutics Ltd, a University of Aberdeen spin-out and privately held company, announced today that its Chairman, Professor Claude Wischik, will be presenting at the 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapyon Friday 28th March at 10:45 a.m. In a session focusing on tau-based therapies and diagnostics for Alzheimer’s disease, Professor Wischik will describe the scientific basis for tau aggregation inhibition and provide an update on the company’s global Phase 3 clinical trials programme.
The annual international conference brings together approximately 1,500 thought leaders in neurology, old-age psychiatry, gerontology and pharmacology to discuss new targets and drugs for the treatment of Alzheimer’s disease, and novel approaches to therapy.
A pioneer in tau pathology research, Professor Wischik’s work led to the scientific discovery that the neurofibrillary tangles first identified by Alois Alzheimer in the brains of Alzheimer’s disease patients are comprised of the microtubule-associated protein tau in the form of filamentous aggregates. This course of research began at Cambridge University in 1985 in the laboratory of Sir Martin Roth (who was the first to correlate tangles in the brainwith Alzheimer’s dementia), and later with Sir Aaron Klug (Nobel Laureate). Professor Wischik subsequently established that these tau protein tangles could be dissolved with pharmaceutical agents that act as ‘tau aggregation inhibitors’. He further demonstrated a direct link between clinical dementia and tau aggregation at the biochemical level, irrespective of amyloid load in the human brain. As Chairman and Co-founder of TauRx Therapeutics, Professor Wischik has led the company to its present stage of conducting global Phase 3 clinical trials of its tau aggregation inhibitor, LMTX™, in mild to moderate Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD).
TauRx Therapeutics Ltd is a spin-out company from the University of Aberdeen, Scotland, and was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company’s tau aggregation inhibitor, LMTX™, is currently in global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTX™ targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to tangles. The clinical trials involve more than 1,500 patients in over 20 countries. Recruitment into the studies is anticipated to be completed by 3rd Quarter 2014. For more information, please visit: http://www.taurx.com
Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol. [Epub ahead of print 2013 Dec 19]. Available at: http://www.sciencedirect.com/science/article/pii/S0006295213007612
Wischik CM, Harrington CR, Storey JMD. TauRx global phase 3 trial in Alzheimer’s disease with tau aggregation inhibitor LMTX. Neurobiol Aging. 2014;35 Suppl 1:S26. Abstract also available at: http://www.siumed.edu/cme/alzheimer/pdf/AbstractBook_WEB2014.pdf